Newsk4xqd2025-02-17T14:10:32+00:00

News

Accelerating the market launch of a medicine: post-development strategies for greater efficiency
Continue reading
Which partners should you choose for preclinical and clinical development?
Continue reading
How should interactions with health agencies be managed?
Continue reading
Procedures for the development of orphan drugs
Continue reading
Key steps in the preclinical development of a drug
Continue reading
Challenges and solutions in the development of drugs for rare diseases
Continue reading
Advertising for medicines: promoting while complying with French regulations
Continue reading
Post-marketing pharmacovigilance obligations in Europe
Continue reading
How to market a drug in France? Centralized Marketing Authorization and other cases
Continue reading
Early access and compassionate use: making a drug available when not authorized in France
Continue reading
What are the EMA’s timelines for the standard and accelerated procedures?
Continue reading
Understanding the differences between the FDA and the EMA: strategic implications for market access
Continue reading